

Kwan Sik Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4154110/publications.pdf>

Version: 2024-02-01

110
papers

4,128
citations

136950

32
h-index

123424

61
g-index

117
all docs

117
docs citations

117
times ranked

5530
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 1344-1354.	10.7	809
2	Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. <i>Liver International</i> , 2010, 30, 546-553.	3.9	225
3	A Liver Stiffness Measurement-Based, Noninvasive Prediction Model for High-Risk Esophageal Varices in B-Viral Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2010, 105, 1382-1390.	0.4	194
4	Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2007, 45, 1172-1178.	7.3	129
5	Usefulness of FibroScan for Detection of Early Compensated Liver Cirrhosis in Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1758-1763.	2.3	122
6	Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. <i>Hepatology</i> , 2007, 46, 1041-1048.	7.3	112
7	Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study. <i>Yonsei Medical Journal</i> , 2005, 46, 399.	2.2	109
8	Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. <i>Hepatology</i> , 2010, 51, 415-421.	7.3	107
9	How Can We Enhance the Performance of Liver Stiffness Measurement Using FibroScan in Diagnosing Liver Cirrhosis in Patients With Chronic Hepatitis B?. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, 66-71.	2.2	94
10	PIVKA-II Is a Useful Tumor Marker for Recurrent Hepatocellular Carcinoma after Surgical Resection. <i>Oncology</i> , 2007, 72, 52-57.	1.9	91
11	Autologous Bone Marrow Infusion Activates the Progenitor Cell Compartment in Patients with Advanced Liver Cirrhosis. <i>Cell Transplantation</i> , 2010, 19, 1237-1246.	2.5	84
12	Long-term Clinical Outcome of Phase IIb Clinical Trial of Percutaneous Injection with Holmium-166/Chitosan Complex (Milican) for the Treatment of Small Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 543-548.	7.0	82
13	Long-term outcome of chronic hepatitis B based on histological grade and stage. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 383-388.	2.8	79
14	Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid. <i>Laboratory Investigation</i> , 2006, 86, 676-686.	3.7	71
15	Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. <i>Gut</i> , 2014, 63, 996-1004.	12.1	67
16	Accuracy of transient elastography in assessing liver fibrosis in chronic viral hepatitis: A multicentre, retrospective study. <i>Liver International</i> , 2015, 35, 2246-2255.	3.9	66
17	CD11b ⁺ Gr1 ⁺ bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice. <i>Hepatology</i> , 2012, 56, 1902-1912.	7.3	65
18	Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. <i>American Journal of Gastroenterology</i> , 2021, 116, 116-124.	0.4	63

#	ARTICLE	IF	CITATIONS
19	Risk Assessment of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis by a Liver Stiffness Measurement-Based Model. <i>American Journal of Gastroenterology</i> , 2011, 106, 1654-1662.	0.4	56
20	Acute Cholecystitis at T2-weighted and Manganese-enhanced T1-weighted MR Cholangiography: Preliminary Study. <i>Radiology</i> , 2003, 227, 580-584.	7.3	55
21	Oxidative stress effect on the activation of hepatic stellate cells. <i>Yonsei Medical Journal</i> , 2001, 42, 1.	2.2	48
22	Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: Results from a multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 526-532.	3.7	46
23	Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1850-1859.e4.	4.4	45
24	Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 196-204.	3.7	43
25	The usefulness of liver stiffness measurement using FibroScan in chronic hepatitis C in South Korea: A multicenter, prospective study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 171-178.	2.8	42
26	Survival of Hepatocellular Carcinoma Patients May be Improved in Surveillance Interval not More Than 6 Months Compared With More Than 6 Months. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 538-544.	2.2	42
27	STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). <i>Journal of Clinical Oncology</i> , 2014, 32, 4006-4006.	1.6	38
28	Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea. <i>Journal of Hepatology</i> , 2001, 35, 92-98.	3.7	37
29	Association of genetic variations in CCR5 and its ligand, RANTES with clearance of hepatitis B virus in Korea. <i>Journal of Medical Virology</i> , 2006, 78, 1564-1571.	5.0	37
30	Antifibrotic effects of magnesium lithospermate B on hepatic stellate cells and thioacetamide-induced cirrhotic rats. <i>Experimental and Molecular Medicine</i> , 2011, 43, 341.	7.7	36
31	Usefulness of urine strip test in the rapid diagnosis of spontaneous bacterial peritonitis. <i>Liver International</i> , 2005, 25, 1197-1201.	3.9	35
32	Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 849-856.	1.6	35
33	Apoptosis of hepatic stellate cells in carbon tetrachloride induced acute liver injury of the rat: analysis of isolated hepatic stellate cells. <i>Journal of Hepatology</i> , 2003, 39, 960-966.	3.7	32
34	A novel liver stiffness measurement-based prediction model for cirrhosis in hepatitis B patients. <i>Liver International</i> , 2010, 30, 1073-1081.	3.9	31
35	The Clinical Impact of Early Detection of the Ymdd Mutant on the Outcomes of Long-Term Lamivudine Therapy in Patients with Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 447-455.	1.0	31
36	Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: A Korean multicenter study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1463-1469.	2.8	26

#	ARTICLE	IF	CITATIONS
37	Prognosis of hepatocellular carcinoma patients with extrahepatic metastasis and the controllability of intrahepatic lesions. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 475-482.	3.3	26
38	Suppression of PPAR β -mediated monoacylglycerol O-acyltransferase 1 expression ameliorates alcoholic hepatic steatosis. <i>Scientific Reports</i> , 2016, 6, 29352.	3.3	26
39	Efficacy and safety of entecavir plus carnitine complex (GODEX $\text{\textcircled{R}}$) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. <i>The GOAL study. Clinical and Molecular Hepatology</i> , 2013, 19, 165.	8.9	26
40	Rescue Monotherapy in Lamivudine-Resistant Hepatitis B e Antigen-Positive Chronic Hepatitis B: Adefovir versus Entecavir. <i>Antiviral Therapy</i> , 2009, 14, 705-712.	1.0	26
41	MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups. <i>Digestive Diseases and Sciences</i> , 2022, 67, 4919-4928.	2.3	26
42	Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation. <i>Cancer Medicine</i> , 2019, 8, 5023-5032.	2.8	25
43	Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study. <i>Oncotarget</i> , 2017, 8, 113213-113224.	1.8	24
44	Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice. <i>Experimental and Molecular Medicine</i> , 2014, 46, e127-e127.	7.7	23
45	Progression of diet induced nonalcoholic steatohepatitis is accompanied by increased expression of kruppel-like-factor 10 in mice. <i>Journal of Translational Medicine</i> , 2014, 12, 186.	4.4	22
46	Villous adenoma of the bile ducts: a case report and a review of the reported cases in Korea. <i>Yonsei Medical Journal</i> , 1999, 40, 84.	2.2	20
47	Partial virological response to entecavir in treatment-naïve patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2011, 16, 469-477.	1.0	20
48	The significance of ICG $\text{\textcircled{R}}$ 15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. <i>Liver International</i> , 2012, 32, 1165-1171.	3.9	19
49	A peroxisome-proliferator activated receptor- β ligand could regulate the expression of leptin receptor on human hepatic stellate cells. <i>Histochemistry and Cell Biology</i> , 2007, 127, 495-502.	1.7	18
50	Clevudine Therapy for 24 Weeks Further Reduced Serum Hepatitis B Virus DNA Levels and Increased ALT Normalization Rates without Emergence of Viral Breakthrough than 12 Weeks of Clevudine Therapy. <i>Intervirology</i> , 2007, 50, 296-302.	2.8	17
51	A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. <i>Hepatology International</i> , 2016, 10, 947-955.	4.2	17
52	Selective deletion of hepatocyte platelet-derived growth factor receptor β and development of liver fibrosis in mice. <i>Cell Communication and Signaling</i> , 2018, 16, 93.	6.5	17
53	Anti-hepatitis A virus seroprevalence among patients with chronic viral liver disease in Korea. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 923-926.	1.6	16
54	Prospective validation of P2/MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis. <i>Liver International</i> , 2010, 30, 860-866.	3.9	16

#	ARTICLE	IF	CITATIONS
55	Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study. <i>Oncologist</i> , 2019, 24, e653-e661.	3.7	16
56	Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial. <i>American Journal of Gastroenterology</i> , 2020, 115, 1217-1225.	0.4	16
57	Platelet-derived growth factor receptor α in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosis. <i>Oncotarget</i> , 2017, 8, 39534-39546.	1.8	16
58	Case Report : Extrahepatic Bile Duct Hepatocellular Carcinoma without Primary Hepatic Parenchymal Lesions. <i>Korean Journal of Internal Medicine</i> , 1996, 11, 169-174.	1.7	16
59	Clinical Efficacy of a 24-months Course of Lamivudine Therapy in Patients with HBeAg Negative Chronic Hepatitis B: A Long-term Prospective Study. <i>Journal of Korean Medical Science</i> , 2010, 25, 882.	2.5	15
60	Assessment of Hepatic Fibrosis Regression by Transient Elastography in Patients with Chronic Hepatitis B Treated with Oral Antiviral Agents. <i>Journal of Korean Medical Science</i> , 2014, 29, 570.	2.5	15
61	Long-Term Follow-Up of Patients after Autologous Bone Marrow Cell Infusion for Decompensated Liver Cirrhosis. <i>Cell Transplantation</i> , 2017, 26, 1059-1066.	2.5	15
62	Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 847-853.	2.8	13
63	Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. <i>World Journal of Gastroenterology</i> , 2019, 25, 4959-4969.	3.3	13
64	Spontaneous bowel perforation during the course of acute pancreatitis: a case report. <i>Yonsei Medical Journal</i> , 1996, 37, 158.	2.2	12
65	Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1481-1491.	4.9	12
66	Impact of postoperative hepatitis B virus reactivation in hepatocellular carcinoma patients who formerly had naturally suppressed virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1019-1027.	2.8	12
67	Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B. <i>Gut and Liver</i> , 2013, 7, 329-334.	2.9	12
68	Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 331-339.	8.9	11
69	Dysphagia due to mediastinal tuberculous lymphadenitis presenting as an esophageal submucosal tumor: a case report. <i>Yonsei Medical Journal</i> , 1995, 36, 386.	2.2	10
70	Anorectal dysfunction in systemic sclerosis. <i>Journal of Korean Medical Science</i> , 1996, 11, 244.	2.5	10
71	Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 346-359.	8.9	10
72	Usefulness of the Controlled Attenuation Parameter for Detecting Liver Steatosis in Health Checkup Examinees. <i>Gut and Liver</i> , 2015, 9, 405-10.	2.9	10

#	ARTICLE	IF	CITATIONS
73	A case of flutamide-induced acute cholestatic hepatitis: a case report. <i>Yonsei Medical Journal</i> , 1996, 37, 225.	2.2	9
74	A case of minute intraductal papillary mucinous tumor of the pancreas presenting with recurrent acute pancreatitis. <i>Yonsei Medical Journal</i> , 2000, 41, 528.	2.2	9
75	A single adenovirus-mediated relaxin delivery attenuates established liver fibrosis in rats. <i>Journal of Gene Medicine</i> , 2016, 18, 16-26.	2.8	9
76	Clinical Course of Virologic Breakthrough after Emergence of YMDD Mutations in HBeAg-Positive Chronic Hepatitis B. <i>Intervirology</i> , 2008, 51, 293-298.	2.8	8
77	Follow-Up Liver Stiffness Measurements after Liver Resection Influence Oncologic Outcomes of Hepatitis-B-Associated Hepatocellular Carcinoma with Liver Cirrhosis. <i>Cancers</i> , 2019, 11, 425.	3.7	8
78	Motion effects on the measurement of stiffness on ultrasound shear wave elastography: a moving liver fibrosis phantom study. <i>Medical Ultrasonography</i> , 2018, 1, 14.	0.8	8
79	Non-alcoholic duct-destructive chronic pancreatitis: recognition before definitive treatment. <i>Yonsei Medical Journal</i> , 1999, 40, 518.	2.2	7
80	Association Between Polymorphism of Tumor Necrosis Factor- β Promoter and Response to Lamivudine Treatment in Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2043-2048.	2.3	7
81	External Validation of P2/MS and Comparison with Other Simple Non-invasive Indices for Predicting Liver Fibrosis in HBV-Infected Patients. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2636-2643.	2.3	7
82	Telbivudine in combination with adefovir versus adefovir monotherapy in HBeAg-positive, lamivudine-resistant chronic hepatitis B. <i>Hepatology International</i> , 2012, 6, 696-706.	4.2	7
83	Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance. <i>BMC Gastroenterology</i> , 2020, 20, 113.	2.0	7
84	Lower gastrointestinal bleeding due to cytomegalovirus ileal ulcers in an immunocompetent man. <i>Yonsei Medical Journal</i> , 2001, 42, 147.	2.2	6
85	Efficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea. <i>Yonsei Medical Journal</i> , 2006, 47, 793.	2.2	6
86	Salvage Chemotherapy with Docetaxel and Epirubicin for Advanced/Metastatic Gastric Cancer. <i>Oncology</i> , 2007, 73, 2-8.	1.9	6
87	Individual prediction model for lamivudine treatment response in hepatitis B virus e antigen-positive chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1049-1055.	2.8	6
88	Antiviral Therapy in Patients With Chronic Hepatitis C-related Hepatocellular Carcinoma Responding to Palliative Treatment. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 557-562.	2.2	6
89	Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir+Asunaprevir therapy in Korean patients with genotype 1b hepatitis C. <i>Virology Journal</i> , 2017, 14, 164.	3.4	5
90	Anti-HBc IgG Levels: A Predictor of HBsAg Seroclearance in Chronic Hepatitis B Patients with Nucleos(t)ide Analogue-Induced HBeAg Seroclearance. <i>Digestive Diseases and Sciences</i> , 2022, 67, 321-328.	2.3	5

#	ARTICLE	IF	CITATIONS
91	A case of paraesophageal hernia repaired by laparoscopic approach. <i>Yonsei Medical Journal</i> , 1996, 37, 151.	2.2	4
92	Peritoneoscopic liver biopsy findings in asymptomatic chronic HBsAg carriers with normal liver function tests and no hepatomegaly. <i>Yonsei Medical Journal</i> , 1996, 37, 295.	2.2	4
93	Clinical characteristics of acute hepatitis A complicated by acute kidney injury. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 144-148.	1.5	4
94	Transitional features of histologic type of non-alcoholic fatty liver disease in Korean young men. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 142-148.	2.8	4
95	Entecavir plus adefovir versus adefovir plus lamivudine in hepatitis B virus e antigen-positive, lamivudine-resistant chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1485-1493.	2.8	4
96	Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1612.	3.7	4
97	Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1362-1372.	2.0	4
98	Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 885-893.	1.6	4
99	Obstructive jaundice and acute cholangitis due to papillary stenosis. <i>Yonsei Medical Journal</i> , 1999, 40, 191.	2.2	3
100	Tissue plasminogen activator and plasminogen activator inhibitor-1 in human choledochal bile. <i>Yonsei Medical Journal</i> , 2000, 41, 119.	2.2	2
101	Prediction of Esophageal Variceal Bleeding in B-Viral Liver Cirrhosis Using the P2/MS Noninvasive Index Based on Complete Blood Counts. <i>Digestion</i> , 2012, 86, 264-272.	2.3	2
102	Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study. <i>Radiation Oncology</i> , 2017, 12, 133.	2.7	2
103	Viral Hepatitis : Focus on Clinical Manifestations of Hepatitis A, B and C. <i>Taehan Uihak Hyophoe Chi the Journal of the Korean Medical Association</i> , 2005, 48, 428.	0.1	2
104	Long-term survival after CCRT and HAIC followed by ALPPS for hepatocellular carcinoma with portal vein invasion: a case report. <i>Journal of Liver Cancer</i> , 2022, 22, 84-90.	1.1	1
105	A large common bile duct stone migrated from the gallbladder through a cholecystohepaticoduochal fistula: an unusual complication of Mirizzi syndrome type II. <i>Yonsei Medical Journal</i> , 1995, 36, 206.	2.2	0
106	Pyloric Brunner's gland hamartoma. <i>Gastrointestinal Endoscopy</i> , 2004, 59, 76.	1.0	0
107	Autoimmune Thyroiditis during Antiviral Therapy with Peginterferon. <i>Journal of Korean Endocrine Society</i> , 2010, 25, 68.	0.1	0
108	Antiviral Therapy for Chronic Hepatitis B. <i>Journal of the Korean Medical Association</i> , 2009, 52, 831.	0.3	0

#	ARTICLE	IF	CITATIONS
109	Detection of Hepatocellular Carcinoma in MR Arterial Portography; Diagnostic Significance as a Pre-Operative Evaluation. Journal of the Korean Radiological Society, 1996, 35, 365.	0.0	0
110	Duodenal metastatic amelanotic melanoma. Gastrointestinal Endoscopy, 2003, 58, 101.	1.0	0